Author

Toshio Tanaka

Axcelead Drug Discovery Partners Inc. (Japan)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Akio Mizutani· 1 shared Daisuke MorishitaiD· 1 shared Hidekazu TokuharaiD· 1 shared Hiroko YamakawaiD· 1 shared Hiroshi Banno· 1 shared Kosuke KawaguchiiD· 1 shared Kosuke YusaiD· 1 shared Mariko TakanoiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Akio Mizutani

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CDK12/13 inhibitor, CTX-439, suppresses tumor growth and potentiates BCL-2 family blockade

Hiroko Yamakawa, Raghda Khatab, Akio Mizutani, Shunsuke Ebara, Takaharu Hirayama, Sunao Tanaka, Yusuke Tarumoto, Midori Sugiyama, Seiichi Sugino, Mariko Takano, Hidekazu Tokuhara, Toshio Tanaka, Hiroshi Banno, Yasuyoshi Arikawa, Yukiko Fukui, , Kosuke Yusa

This study develops CTX-439, a CDK12/13 inhibitor, showing anti-tumor effects and resistance mechanisms, and proposes combining it with BCL-2 family inhibitors for cancer treatment.

bioRxiv · Feb 20, 2026 · PreprintCancer Biology